Literature DB >> 25858582

Decitabine improves outcomes in older patients with acute myeloid leukemia and higher blast counts.

Tapan M Kadia1, Xavier G Thomas2, Anna Dmoszynska3, Agnieszka Wierzbowska4, Mark Minden5, Christopher Arthur6, Jacques Delaunay7, Farhad Ravandi1, Hagop Kantarjian1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25858582      PMCID： PMC4478207          DOI： 10.1002/ajh.24036

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  11 in total

1.  Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome.

Authors:  Hagop Kantarjian; Susan O'brien; Jorge Cortes; Francis Giles; Stefan Faderl; Elias Jabbour; Guillermo Garcia-Manero; William Wierda; Sherry Pierce; Jianqin Shan; Elihu Estey
Journal:  Cancer       Date:  2006-03-01       Impact factor: 6.860

2.  Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemia.

Authors:  Ellen K Ritchie; Eric J Feldman; Paul J Christos; Sarah D Rohan; Catherine B Lagassa; Cindy Ippoliti; Joseph M Scandura; Karen Carlson; Gail J Roboz
Journal:  Leuk Lymphoma       Date:  2013-02-07

3.  A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy.

Authors:  Michael Lübbert; Björn H Rüter; Rainer Claus; Claudia Schmoor; Mathias Schmid; Ulrich Germing; Andrea Kuendgen; Volker Rethwisch; Arnold Ganser; Uwe Platzbecker; Oliver Galm; Wolfram Brugger; Gerhard Heil; Björn Hackanson; Barbara Deschler; Konstanze Döhner; Anne Hagemeijer; Pierre W Wijermans; Hartmut Döhner
Journal:  Haematologica       Date:  2011-11-04       Impact factor: 9.941

4.  Azacitidine for the treatment of patients with acute myeloid leukemia: report of 82 patients enrolled in an Italian Compassionate Program.

Authors:  Luca Maurillo; Adriano Venditti; Alessandra Spagnoli; Gianluca Gaidano; Dario Ferrero; Esther Oliva; Monia Lunghi; Alfonso M D'Arco; Alessandro Levis; Domenico Pastore; Nicola Di Renzo; Alberto Santagostino; Vincenzo Pavone; Francesco Buccisano; Pellegrino Musto
Journal:  Cancer       Date:  2011-07-14       Impact factor: 6.860

5.  Cancer statistics, 2014.

Authors:  Rebecca Siegel; Jiemin Ma; Zhaohui Zou; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2014-01-07       Impact factor: 508.702

6.  Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia.

Authors:  Amanda F Cashen; Gary J Schiller; Margaret R O'Donnell; John F DiPersio
Journal:  J Clin Oncol       Date:  2009-12-21       Impact factor: 44.544

7.  Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia.

Authors:  Pierre Fenaux; Ghulam J Mufti; Eva Hellström-Lindberg; Valeria Santini; Norbert Gattermann; Ulrich Germing; Guillermo Sanz; Alan F List; Steven Gore; John F Seymour; Hervé Dombret; Jay Backstrom; Linda Zimmerman; David McKenzie; C L Beach; Lewis R Silverman
Journal:  J Clin Oncol       Date:  2009-12-21       Impact factor: 44.544

8.  Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia.

Authors:  Hagop M Kantarjian; Xavier G Thomas; Anna Dmoszynska; Agnieszka Wierzbowska; Grzegorz Mazur; Jiri Mayer; Jyh-Pyng Gau; Wen-Chien Chou; Rena Buckstein; Jaroslav Cermak; Ching-Yuan Kuo; Albert Oriol; Farhad Ravandi; Stefan Faderl; Jacques Delaunay; Daniel Lysák; Mark Minden; Christopher Arthur
Journal:  J Clin Oncol       Date:  2012-06-11       Impact factor: 44.544

9.  Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia.

Authors:  Hagop Kantarjian; Farhad Ravandi; Susan O'Brien; Jorge Cortes; Stefan Faderl; Guillermo Garcia-Manero; Elias Jabbour; William Wierda; Tapan Kadia; Sherry Pierce; Jianqin Shan; Michael Keating; Emil J Freireich
Journal:  Blood       Date:  2010-07-28       Impact factor: 22.113

10.  Azacitidine in untreated acute myeloid leukemia: a report on 149 patients.

Authors:  Sylvain Thépot; Raphael Itzykson; Valerie Seegers; Christian Recher; Emmanuel Raffoux; Bruno Quesnel; Jacques Delaunay; Thomas Cluzeau; Anne Marfaing Koka; Aspasia Stamatoullas; Marie-Pierre Chaury; Caroline Dartigeas; Stéphane Cheze; Anne Banos; Pierre Morel; Isabelle Plantier; Anne-Laure Taksin; Jean Pierre Marolleau; Cecile Pautas; Xavier Thomas; Francoise Isnard; Blandine Beve; Yasmine Chait; Agnes Guerci; Norbert Vey; Francois Dreyfus; Lionel Ades; Norbert Ifrah; Herve Dombret; Pierre Fenaux; Claude Gardin
Journal:  Am J Hematol       Date:  2014-02-06       Impact factor: 10.047
View more
  13 in total

Review 1.  Bone marrow evaluation for diagnosis and monitoring of acute myeloid leukemia.

Authors:  Mary-Elizabeth Percival; Catherine Lai; Elihu Estey; Christopher S Hourigan
Journal:  Blood Rev       Date:  2017-02-02       Impact factor: 8.250

Review 2.  Hypomethylating Agents as a Therapy for AML.

Authors:  Claude Gardin; Hervé Dombret
Journal:  Curr Hematol Malig Rep       Date:  2017-02       Impact factor: 3.952

Review 3.  How and when to decide between epigenetic therapy and chemotherapy in patients with AML.

Authors:  Hervé Dombret; Raphael Itzykson
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

Review 4.  Future prospects of therapeutic clinical trials in acute myeloid leukemia.

Authors:  Maliha Khan; Armaghan-E-Rehman Mansoor; Tapan M Kadia
Journal:  Future Oncol       Date:  2016-10-24       Impact factor: 3.404

Review 5.  New drugs in acute myeloid leukemia.

Authors:  T M Kadia; F Ravandi; J Cortes; H Kantarjian
Journal:  Ann Oncol       Date:  2016-01-22       Impact factor: 32.976

6.  Decitabine as a First-Line Treatment for Older Adults Newly Diagnosed with Acute Myeloid Leukemia.

Authors:  Hyunsung Park; Haerim Chung; Jungyeon Lee; Jieun Jang; Yundeok Kim; Soo Jeong Kim; Jin Seok Kim; Yoo Hong Min; June Won Cheong
Journal:  Yonsei Med J       Date:  2017-01       Impact factor: 2.759

Review 7.  MYC-Master Regulator of the Cancer Epigenome and Transcriptome.

Authors:  Candace J Poole; Jan van Riggelen
Journal:  Genes (Basel)       Date:  2017-05-13       Impact factor: 4.096

8.  Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study.

Authors:  Antonio M Almeida; Thomas Prebet; Raphael Itzykson; Fernando Ramos; Haifa Al-Ali; Jamile Shammo; Ricardo Pinto; Luca Maurillo; Jaime Wetzel; Pellegrino Musto; Arjan A Van De Loosdrecht; Maria Joao Costa; Susana Esteves; Sonja Burgstaller; Reinhard Stauder; Eva M Autzinger; Alois Lang; Peter Krippl; Dietmar Geissler; Jose Francisco Falantes; Carmen Pedro; Joan Bargay; Guillermo Deben; Ana Garrido; Santiago Bonanad; Maria Diez-Campelo; Sylvain Thepot; Lionel Ades; Wolfgang R Sperr; Peter Valent; Pierre Fenaux; Mikkael A Sekeres; Richard Greil; Lisa Pleyer
Journal:  Int J Mol Sci       Date:  2017-04-14       Impact factor: 5.923

Review 9.  Beyond the Edge of Hypomethylating Agents: Novel Combination Strategies for Older Adults with Advanced MDS and AML.

Authors:  Anne Sophie Kubasch; Uwe Platzbecker
Journal:  Cancers (Basel)       Date:  2018-05-24       Impact factor: 6.639

10.  Quantitative proteomic analysis of histone modifications in decitabine sensitive and resistant leukemia cell lines.

Authors:  Chunchao Zhang; Jinfeng Suo; Hiroyuki Katayama; Yue Wei; Guillermo Garcia-Manero; Samir Hanash
Journal:  Clin Proteomics       Date:  2016-07-05       Impact factor: 3.988
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.